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High blood pressure is the leading cause of morbidity and mortality worldwide. In fact, 
according to the estimations by the Global Burden of Disease project, it was the most 
important risk factor among women and second among men in 2016, responsible for about 90 
million and 122 million disability-adjusted life-years, respectively.1 In addition to being a 
major risk factor for coronary heart disease and stroke, as well as a key component of 
metabolic syndrome, it is often considered as a distinct illness on its own right.2,3 
Prevalence of hypertension in Asian countries, particularly in China, is especially high. It is 
estimated that in this country nearly half of the adult population between the ages of 35 and 
75 years has high blood pressure, with only half of these individuals are aware of their 
condition, less than one third are treated and less than 10% are treated adequately.4 
Considering these striking numbers and the public health importance which they impose, 
research into the determinants, mechanism or consequences of hypertension is always 
valuable and relevant, particularly in this population. 
In a related paper,5 Wang and colleagues examined blood pressure and blood pressure change 
in relation to all-cause and cause specific mortality among adults in the Yinzhou district in 
Eastern China.They used data from electronic health records which allowed them to include 
nearly 170,000 individuals in their analysis. Further advantage is that for more than 60,000 
participants two waves of blood pressure measurements were available, which provided the 
opportunity to examine the long-term health effect of blood pressure change over a 2-year 
period. Conventional and standardised methods for data collection and statistical analysis 
were applied, and the competing risk assessment, the extensive sensitivity analyses and the 
propensity score adjustment added further value and strength to the work.  
In terms of the results, not surprisingly, and consistently with most previous studies,6 the 
authors found that hypertension predicted higher all-cause and CVD mortality, while 
hypotension (blood pressure lower than 90/60 mmHg) also increased the risk. The findings 
got additional confirmation by testing the linearity of these associations in specific blood 
pressure groups. Clear positive link emerged only in participants with systolic or diastolic 
blood pressure higher than 140 mmHg or 90 mmHg, respectively. The longitudinal analysis 
which looked at blood pressure change in relation to mortality outcomes showed similar 
results, suggesting high risk of CVD or all-cause death if blood pressure during the examined 
2-years period changed from normotension to prehypertension or from prehypertension to 
hypertension.  
Interestingly, the relationship between blood pressure and cancer mortality, as well as with 
other causes of death, was much less obvious. Only hypotensive individuals showed 
significantly higher riskof cancer, and the link with hypertension (and particularly with 
prehypertension) seem to be inverse. The available evidence regarding the blood pressure-
cancerassociation is rather inconsistent, and in fact, there are several studies which indicate 
opposite direction to the current findings.7,8 Although the authors provide a potential 
explanation, further exploration of the relationship between blood pressure and cancer risk is 
clearly needed.  
The study by Wang and colleagues is not without limitations and there are several details 
which need to be taken into account when interpreting the results. Most of these are 
adequately identified and described by the authors, and here we would just emphasise the 
relatively short follow-up time (6 years) and the potential misclassification due to 
measurement bias, both of which can contribute to the above detailed findings regarding the 
relationship between blood pressure and cancer.  
This study emphasises the importance of appropriate blood pressure control and highlights 
the potential consequences if it is not achieved. Considering the high prevalence of this 
condition in China, as well as the apparently low proportion of well-controlled cases,4 this is 
a particularly important message there, but relevant for any country or society. Through 
prevention and treatment, public health professionals and clinicians have a joint responsibility 
to reduce the disease burden attributable to hypertension anywhere. 
More research is needed to assess whether patients with higher levels of blood pressure can 
benefit from preventive measures or therapeutic interventions, especially in relation to 
different ethnicities and therapeutic responses, aiming for a lower global mortality rate 
related to altered blood pressure levels. 
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